Quick Answer
Foghorn Therapeutics Inc. reported Operating Income of -$86.39 million for fiscal year 2025.
Foghorn Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$86.39M | +15.9% |
| 2024 | -$102.68M | +4.8% |
| 2023 | -$107.91M | +7.9% |
| 2022 | -$117.14M | -16.3% |
| 2021 | -$100.73M | -47.0% |
| 2020 | -$68.53M | -34.2% |
| 2019 | -$51.08M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$18.50M | +22.4% | +12.3% |
| June 30, 2025 | -$21.10M | +20.8% | +7.9% |
| March 31, 2025 | -$22.91M | +18.7% | +3.9% |
| September 30, 2024 | -$23.85M | -39.6% | +10.4% |
| June 30, 2024 | -$26.63M | +16.9% | +5.5% |
| March 31, 2024 | -$28.19M | +15.4% | -65.1% |
| September 30, 2023 | -$17.08M | +39.6% | +46.7% |
| June 30, 2023 | -$32.05M | -9.8% | +3.8% |
- Foghorn Therapeutics Inc. showed an increase of +15.9% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Foghorn Therapeutics Inc.’s operating income has declined by 69.1% (from -$51.08 million to -$86.39 million).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: